# US 2012/0251478 A1 · Method for treatment of a glomerular disease comprising administration of anion exchange resin

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2012/0251478 A1
- Document ID: US20120251478A1
- Status: Published application
- Kind: A1
- Application number: 13/441,283
- Filed: 2012-04-06
- Published: 2012-10-04
- Earliest claimed: 2006-06-16
- Inventors: Masahiko YAMAMORI
- Web page: https://patentgrep.com/patent/US20120251478A1

## CPC

- A61K 31/785: Polymers containing nitrogen
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 13/12: of the kidneys
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Provided is a novel prophylactic and/or therapeutic agent for glomerular disease wherein a pharmaceutically acceptable anion exchange resin, typified by colestimide, is an active ingredient thereof.

## Claims

### Claim at position 1

1-16. (canceled)

### Claim 17

A method for treatment of a glomerular disease, comprising administering a therapeutically effective amount of colestimide to a patient in need thereof, wherein the glomerular disease is diabetic nephropathy or IgA nephropathy.

### Claim 18 (depends on 17)

The method of claim 17, wherein the glomerular disease is IgA nephropathy.

### Claim 19 (depends on 17)

The method of claim 17, wherein the glomerular disease is diabetic nephropathy.

### Claim 20 (depends on 19)

The method of claim 19, wherein the diabetic nephropathy is in the early nephropathy stage.

### Claim 21 (depends on 17)

The method of claim 17, which reduces the urinary albumin level.

### Claim 22 (depends on 17, 18, 19, 20)

The method of any one of claims 17, 18, 19, 20, and 21, to be used in patients already receiving an angiotensin converting enzyme inhibitor or an angiotensin receptor blocker.

### Claim 23 (depends on 17, 18, 19, 20)

The method of any one of claims 17, 18, 19, 20, and 21, wherein an angiotensin converting enzyme inhibitor or an angiotensin receptor blocker is used concurrently, separately, or sequentially.

### Claim 24 (depends on 17, 18, 19, 20)

The method of any one of claims 17, 18, 19, 20, and 21, to be used for patients with normal blood pressure.
